Are you writing a dissertation full-time on a history of healthcare or healthcare topic in the humanities or social sciences? This is broadly defined as the study of past practices and epistemologies related to human health, healthcare, and disease. To be eligible, you must be a Canadian citizen or permanent resident with ABD (All But Dissertation) status by the December of the application year, with preference given to those individuals in the final stages of completion (within 2 years of graduation). Applicants who have received a Doctoral Completion Award in the past are not eligible to apply for this award.

This grant is for Canadian citizens or permanent residents who are candidates embarking on full-time post-doctoral studies. It supports emerging scholars as they begin or complete projects featuring the study, analysis, and interpretation of past practices, philosophies, and/or epistemologies related to human health, healthcare, and/or disease or the education of health professionals. If this describes you, add to your experience by conducting research in Canada or abroad with our funding.

This funding supports small-budget proposals for research projects in the history of healthcare and allied disciplines, such as science and technology studies, sociology, anthropology, and classics. Your project must strive to advance the history of health, healthcare and disease, or the education of health professionals. We’re partial to projects that consider the Canadian context, and these may include requests for seed money to develop research initiatives. Your work should benefit the broader community of practitioners in the field. Successful applicants must produce one or more conference papers or publications/presentations within a year of this grant’s completion.

Funds Available

The Brain Health Medicines Scholar Award provides funding and drug development support to researchers whose work aims to treat, prevent or cure Alzheimer's disease and related dementias.

CIHR-IG is pleased to be partnering with approximately 34 international funding organizations in the context of this European Rare Diseases Research Alliance (ERDERA) Joint Transnational Call (JTC) 2025. CIHR-IG is committed to expanding and improving the diagnosis and treatment of rare diseases by creating the conditions needed to bring together creative, dynamic, interdisciplinary teams of researchers from across Canada and the European Community (EC) to collaborate for better health outcome for the rare disease patient community.

The topic of the call is pre-clinical therapy studies for rare diseases using small molecules and biologicals – development and validation.

Projects should focus on a group of rare diseases or on a single rare disease if there is no valid rationale/evidence for the benefit of grouping diseases. If focusing on a single rare disease, applicants must clearly specify why working on a group of rare diseases is not appropriate. The classification of rare diseases follows the European definition, i.e. a disease affecting not more than five in 10,000 persons in the European Community, EC associated states, and Canada.

The specific objectives of this funding opportunity are to:

• Advance the understanding of the biological mechanisms underlying cancer etiology, genesis, and/or risk linked with host, lifestyle, environmental, social, and other factors to enable improvements in cancer prevention, early detection, and risk reduction at the individual and/or population-level.
• Foster and enable interdisciplinary team science by connecting diverse researchers across discovery, clinical, health services, and population health research, and knowledge users and knowledge holders, whose collaborative efforts are required to achieve an improved understanding of the biological mechanisms and associated determinants of health that influence cancer risk and development.
• Bridge the gap between research and clinical/public health practice through knowledge mobilization.
• Strengthen and promote research capacity in cancer prevention, early detection, and risk reduction through interdisciplinary and experiential-based approaches.

The Forest Sector Investment and Innovation Program (FSIIP) provides funding for strategic investments in the forest sector that:

• improve productivity and innovation
• enhance competitiveness
• support new market access
• provide benefits to Ontario’s broader forest sector
• strengthen regional economies

Support is available under two project categories – business projects and collaboration projects.

The R&D Partnership Fund – Electric Vehicle (EV) – Stream 2 Program supports projects related to the development and demonstration of technologies in electric vehicles (EV) and battery manufacturing technologies in the following priority areas:

• Mass light vehicles, such as cars, trucks and vans
• Heavy duty vehicles, including commercial vehicles, trucks, buses, recreational vehicles (RVs), and others used for goods movement
• Charging infrastructure
• Intelligent Transportation Systems (ITS)
• Transit-supportive systems and vehicles